Current Report Filing (8-k)
January 13 2020 - 7:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
January 13, 2020
ADMA BIOLOGICS, INC.
|
(Exact name of registrant as specified in its charter)
|
|
|
|
Delaware
|
001-36728
|
56-2590442
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
|
|
465 State Route 17, Ramsey, New Jersey
|
07446
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (201) 478-5552
|
(Former name or former address, if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
o Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common stock, par value $0.0001 per share
|
ADMA
|
Nasdaq Global Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
ADMA Biologics, Inc., a Delaware corporation
(the “Company”) hereby furnishes the Corporate Presentation the Company expects to present to analysts and investors
on or after January 13, 2020. The Company expects to use the Corporate Presentation, in whole or in part, and possibly with modifications,
from time to time in connection with presentations to potential investors, strategic partners, industry analysts and others. The
Corporate Presentation is attached hereto as Exhibit 99.1 and is incorporated by reference herein, and is available under the “Company
Information” tab in the “Investors” section of the Company’s website, located at www.admabio.com.
By furnishing this Current Report on Form 8-K
and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this
report that is required to be disclosed solely by reason of Regulation FD.
The information contained in the Corporate
Presentation is summary information that is intended to be considered in the context of the Company’s Securities and Exchange
Commission (“SEC”) filings and other public announcements that the Company may make, by press release or otherwise,
from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this
report, except as may be required by the federal securities laws, although it may do so from time to time as its management believes
is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases
or through other public disclosure.
The information furnished pursuant to this
Current Report on Form 8-K, including Exhibit 99.1 hereto, shall not be considered “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities
of that section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933,
as amended, or under the Exchange Act, unless the Company expressly sets forth in such future filings that such information is
to be considered “filed” or incorporated by reference therein.
(d) Exhibits
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
January 13, 2020
|
ADMA Biologics, Inc.
|
|
|
|
By:
|
/s/ Brian Lenz
|
|
|
Name:
|
Brian Lenz
|
|
|
Title:
|
Executive Vice President and Chief Financial Officer
|